Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service lumbar fusion cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (239 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 30 | 1,272 | 33% |
| 2020 | 26 | 1,246 | 36% |
| 2021 | 38 | 1,560 | 39% |
| 2022 | 33 | 1,526 | 41% |
| 2023 | 40 | 1,614 | 43% |
| 2024 | 40 | 1,764 | 45% |
| 2025 from claims | – | 1,643 1,508–1,738 | 46% |
| 2026 forecast | – | 1,732 1,524–1,998 | 46% |
| 2027 forecast | – | 1,821 1,557–2,170 | 47% |
| 2028 forecast | – | 1,915 1,598–2,345 | 47% |
| 2029 forecast | – | 2,014 1,645–2,525 | 47% |
| 2030 forecast | – | 2,117 1,696–2,713 | 48% |
Posterolateral, interbody, and anterior lumbar fusion with instrumentation. Professional codes (what the surgeon bills): CPT 22612, 22630, 22633, 22558; the hospital bills MS-DRG 453, 454, 455, 459, 460, 402, 426, 427, 428, 447, 448, 450, 451, 523, 524, 525.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 44% of the cases CMS names in New Jersey; 27 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 63% inpatient hospital, 26% hospital outpatient, 11% surgery center. The share outside the hospital has moved +11 pts since 2019, so more of this market is decided in surgery centers and offices each year.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 89 | 3,644−1.8%/yr | −1.8%/yr | 2.6 | 3% | 3,820 in 2030+0.8%/yr |
| New York | 96 | 3,407−0.3%/yr | −0.3%/yr | 1.8 | 1% | 4,050 in 2030+2.9%/yr |
| Massachusetts | 61 | 2,186+0.3%/yr | +0.3%/yr | 2.3 | 0% | 2,550 in 2030+2.6%/yr |
| Connecticut | 25 | 965+0.5%/yr | +0.5%/yr | 2.8 | 0% | 1,000 in 2030+0.5%/yr |
| New Hampshire | 6 | 324−6.1%/yr | −6.1%/yr | 1.4 | 0% | 500 in 2030+7.7%/yr |
| Rhode Island | 8 | 294−2.1%/yr | −2.1%/yr | 3.1 | 0% | 460 in 2030+7.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 62 | 2,530−1.6%/yr | −1.6%/yr | 2.30.9× | 4% | 2,680 in 2030+1%/yr |
| Cervical fusion & disc arthroplasty | 15 | 957+0.5%/yr | +0.5%/yr | 0.90.8× | 0% | 1,050 in 2030+1.5%/yr |
| Kyphoplasty & vertebroplasty | 6 | 624−5.3%/yr | −5.3%/yr | 0.60.7× | 59% | 630 in 2030+0.1%/yr |
| SI joint fusion | 3 | 157+9.2%/yr | +9.2%/yr | 0.11.3× | 100% | 260 in 2030+9.1%/yr |
Lumbar fusion in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with Pennsylvania
VB Spine leads with 36% of company spending on these surgeons in 2025, −2 pts on 2024.
In 2025, 22 companies reported engagement with New Jersey’s surgeons worth $407K in consulting, speaking, meals and travel tied to these products, about $10K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 87 clearances and approvals in the category, 12 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.